Lipidated peptide inhibitors of the interleukin-23 receptor
Patent Information
- Application Number
- JP2024501765
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2021-07-14
- Filing Date
- 2022-07-14
- Publication Date
- 2025-07-23
AI Technical Summary
There is a need for effective small molecule and/or polypeptide therapeutics that can selectively inhibit IL-23 signaling to treat autoimmune inflammatory diseases such as psoriasis, psoriatic arthritis, inflammatory bowel disease, ulcerative colitis, and Crohn's disease, particularly those that can be administered orally and target IL-23R from the luminal side of the intestine.
Development of lipidated cyclic peptide inhibitors that bind to IL-23R, inhibiting IL-23 binding and signal transduction, which can be administered via various routes including oral administration, providing therapeutic benefit by targeting IL-23R from the luminal side of the intestine.
The lipidated cyclic peptide inhibitors exhibit enhanced properties like longer in vivo half-life and improved bioavailability, offering a non-injectable treatment option for mild to severe psoriasis and local intestinal inflammation in inflammatory bowel diseases.